Stockreport

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen Ltd. - Ordinary Shares  (CGEN) 
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: cgen.com/investors/overview
PDF New approach to harness cytokine biology to treat cancer patients advances to the clinicFirst patient dosed with potential first-in-class anti-IL-18 binding protein anti [Read more]